1. Home
  2. Directory
  3. New Mexico
  4. Las Cruces
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1306044839

RENE JOUKHADAR M.D.
Prescription History 1306044839
Internal Medicine - Endocrinology, Diabetes & Metabolism in Las Cruces, NM

NPI Status: Active since July 05, 2007

Contact Information

2904 HILLRISE DR
LAS CRUCES, NM
ZIP 88011
Phone: (575) 222-4074
Fax: (575) 222-4078

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for RENE JOUKHADAR M.D., an active Endocrinology, Diabetes & Metabolism specialist practicing in Las Cruces, NM. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 119 documented patient claims. Among these therapy options, the most frequently utilized medication is Levothyroxine Sodium, which accounts for 102 claims alone.

Medication Index

L
M
No matching medications currently found on file.

Levothyroxine Sodium

Generic Formulation: Levothyroxine SodiumSpecialty: Endocrinology
Provider Metrics Summary
Total Claims 102
30-Day Fills 295.5
Days Supply 8,834
NM State Average Benchmarks
Peer Average Claims140.0
Peer Average 30-Day Fills337.0
Peer Average Days Supply9,997
Conservative Utilization

This provider writes prescriptions for this formulation 27.1% less frequently than the standard regional baseline metric for practitioners inside NM. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,762.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.28

State Avg Cost Per Claim

$17.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.

Therapeutic Applications

Levothyroxine is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally produced by the thyroid gland. Low thyroid hormone levels can occur naturally or when the thyroid gland is injured by radiation/medications or removed by surgery. Having enough thyroid hormone is important for maintaining normal mental and physical activity. In children, having enough thyroid hormone is important for normal mental and physical development. This medication is also used to treat other types of thyroid disorders (such as thyroid cancer). This medication should not be used to treat infertility unless it is caused by low thyroid hormone levels.

Methimazole

Generic Formulation: MethimazoleSpecialty: Endocrinology
Provider Metrics Summary
Total Claims 17
30-Day Fills 39.8
Days Supply 1,179
NM State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills79.6
Peer Average Days Supply2,370
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.8% less volume than the regional standard for practitioners inside NM. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $276.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.25

State Avg Cost Per Claim

$16.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.

Therapeutic Applications

Methimazole is used to treat overactive thyroid (hyperthyroidism). It works by stopping the thyroid gland from making too much thyroid hormone.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like RENE JOUKHADAR M.D. provides transparency into local medical care patterns within Las Cruces, NM.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Endocrinology, Diabetes & Metabolism** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.